Áttétes emlőrák: vizsgálatok itt: Kína
187 of 224 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
- Életkor
- 18 év and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - 3. fázisTaking peopleEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Where
- Anhui, Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqicun, Dalian, Deyang, Fuyang, Fuzhou, Guandong, Guangdong, Guangzhou, Haikou, Hangzhou, Hebei, Hubei, Hunan, Jieyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Nanchang, Nanjing, Nanning, Nanyang, Neijiang, Ningbo, Pingdingshan, Qingdao, Quanzhou, Shang’ai, Shanghai, Shanxi, Shaoyang, Shenyang, Shouguang, Sichuan, Tianjin, Ürümqi, Wenzhou, Wuhan, Wuhu, Xi Ail, Xiamen, Xinzheng, Xuzhou, Yuncheng, Zhejiang, Zhengzhou, Zhongshan, Zhumadian
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Where
- Baoding, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanchang, Nanning, Shantou, Tianjin, Wuhan
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00 - 2. fázisFut, nem toborozStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Where
- Beijing, Hangzhou, Wuhan, Xi’an, Zhengzhou
- Életkor
- 18 év and over
- People
- 430 worldwide
- Run by
- Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00 - 1/2. fázisTaking peopleA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Where
- Bengbu, Changchun, Chengdu, Chongqing, Huizhou, Nanning, Shanghai, Xi'an
- Életkor
- 18 év and over
- People
- 380 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06827236 · EU 2024-517979-20-00 - 2/3. fázisTaking peopleRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Where
- Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, HangzhouZhejiang, Hefei, Jiangmen, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Ürümqi, Wuhan, Xi'an
- Életkor
- 18 év and over
- People
- 650 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Where
- Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jiangmen, Jinan, Jinhua, Kunming, Nanning, Shantou, Tianjin, Ürümqi, Xi'an, Xi’an, Xiangyang
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00 - 3. fázisTaking peopleA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Where
- Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou Fujian, Guangzhou, Harbin, Jiangmen, Ningbo, Shanghai, Shantou, Tianjin, Wuhan, Zhanjiang
- Életkor
- 18 év and over
- People
- 800 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00 - 3. fázisTaking peopleA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linhai, Nanchang, Nanjing, Nanning, Ürümqi, Wanzhou, Xi'an, Xiangyang, Zhengzhou
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00 - 2. fázisTaking peopleStudy of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 140
- Run by
- Fudan University
See details and how to joinNCT07581795 - 3. fázisTaking peopleSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Where
- Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jining, Kunming, Liuzhou, Luoyang, Nanchang, Nanjing, Shandong, Shanghai, Shenyang, Shijiazhuang, Tianjin, Weifang, Wuhan, Xiamen, Xi'an, Xiangyang, Xinxiang, Zhengzhou
- Életkor
- 18 év and over
- People
- 788 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00 - 3. fázisBefejeződöttA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Where
- Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Tianjin, Wuhan, Xi'an, Zhejiang
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00 - 3. fázisNot yet taking people in KínaA Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 1050
- Run by
- Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07894328 - 3. fázisNot yet taking people in KínaTrastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
- Where
- Guangzhou
- Életkor
- 18 év to 80 év
- People
- 226
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07892274 - 1/2. fázisTaking peopleA Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 528
- Run by
- Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT06555068 - 2. fázisTaking peopleA Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 120
- Run by
- Shanghai Best-Link Bioscience, LLC
See details and how to joinNCT07658183 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Where
- Baoding, Beijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Wenzhou, Wuhan, Xi'an
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00 - 2. fázisTaking peopleAnlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
- Where
- Zhengzhou
- Életkor
- 18 év and over
- People
- 134
- Run by
- Henan Cancer Hospital
See details and how to joinNCT05296577 - 2. fázisTaking peopleARX788 in HER2-positive Metastatic Breast Cancer Patients
- Where
- Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 44
- Run by
- Henan Cancer Hospital
See details and how to joinNCT06663748 - 1. fázisTaking peopleBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Where
- Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shanghai, Shenyang
- Életkor
- 18 év and over
- People
- 433 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06120283 · EU 2023-506888-34-00 - 2. fázisTaking peopleSHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
- Where
- Zhengzhou
- Életkor
- 18 év and over
- People
- 30
- Run by
- Henan Cancer Hospital
See details and how to joinNCT07125950 - 2. fázisTaking peopleThe Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 184
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07203729 - 2. fázisTaking peopleSMP-656 for HER2-Positive Advanced Breast Cancer
- Where
- Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi’an, Zhengzhou
- Életkor
- 18 év and over
- People
- 60
- Run by
- Chengdu SciMount Pharmatech Co., Ltd.
See details and how to joinNCT07726342 - 2. fázisTaking peopleA Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 180
- Run by
- MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT06439771 - 2. fázisTaking peopleA Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 87
- Run by
- Shenyang Sunshine Pharmaceutical Co., LTD.
See details and how to joinNCT07757230